{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:50:33Z","timestamp":1787169033157,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.msard.2025.106416","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T08:44:02Z","timestamp":1743929042000},"page":"106416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5036","authenticated-orcid":false,"given":"Gelvana Fl\u00e1vio Barreto","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0899-5789","authenticated-orcid":false,"given":"Andrea de Carvalho Anacleto Ferrari","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-0430","authenticated-orcid":false,"given":"Eitan Naaman","family":"Berezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106416_bib0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.msard.2019.07.026","article-title":"Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab","volume":"35","author":"Aguirre","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106416_bib0013","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1590\/0004-282x-anp-2021-0162","volume":"79","author":"Becker","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"issue":"3","key":"10.1016\/j.msard.2025.106416_bib0034","first-page":"160","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106416_bib0024","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1590\/0004-282x20180083","article-title":"Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis","volume":"76","author":"Branco","year":"2018","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106416_bib0015","series-title":"Manual Dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais","year":"2023"},{"issue":"12","key":"10.1016\/j.msard.2025.106416_bib0031","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1111\/ene.15055","article-title":"Toxoplasma gondii and multiple sclerosis: a systematic review and meta-analysis","volume":"28","author":"Cicero","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106416_bib0033","doi-asserted-by":"crossref","unstructured":"Eichau S., L\u00f3pez Ruiz R., Cast\u00f3n Osorio J.J., et al. 2020. Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. Neurologia (Engl. Ed). 35(6):440\u20133. https:\/\/doi.org\/10.1016\/j.nrl.2018.03.015.","DOI":"10.1016\/j.nrleng.2018.03.024"},{"issue":"8","key":"10.1016\/j.msard.2025.106416_bib0001","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open. Forum. Infect. Dis."},{"issue":"13","key":"10.1016\/j.msard.2025.106416_bib0009","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2025.106416_bib0029","article-title":"Differential diagnosis of multiple sclerosis in Latin America","volume":"3","author":"Fragoso","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.msard.2025.106416_bib0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1055\/s-0042-1754348","article-title":"Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach","volume":"80","author":"Gomes","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"issue":"1","key":"10.1016\/j.msard.2025.106416_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","article-title":"Epidemiology of multiple sclerosis","volume":"172","author":"Leray","year":"2016","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.msard.2025.106416_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/cid\/ciab856","article-title":"Comorbidity increases the risk of invasive meningococcal disease in adults","volume":"75","author":"Lundbo","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.msard.2025.106416_bib0037","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1177\/1352458521991433","article-title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination","volume":"27","author":"Mhanna","year":"2021","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106416_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106416_bib0007","article-title":"Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis","volume":"4","author":"Navas","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2025.106416_bib0011","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/WCO.0000000000000929","article-title":"Vaccinations in multiple sclerosis patients receiving disease-modifying drugs","volume":"34","author":"Otero-Romero","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106416_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nrl.2020.02.006","article-title":"Recomendaciones para la vacunaci\u00f3n en pacientes con esclerosis m\u00faltiple candidatos a terapias inmunosupresoras: documento de consenso espa\u00f1ol","volume":"36","author":"Otero-Romero","year":"2021","journal-title":"Neurolog\u00eda"},{"issue":"8","key":"10.1016\/j.msard.2025.106416_bib0021","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/ene.15809","article-title":"European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs","volume":"30","author":"Otero-Romero","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106416_bib0023","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.neurol.2021.04.011","article-title":"Infections and multiple sclerosis: recommendations from the French Multiple Sclerosis Society","volume":"177","author":"Papeix","year":"2021","journal-title":"Rev. Neurol. (Paris)"},{"issue":"6","key":"10.1016\/j.msard.2025.106416_bib0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive multifocal leukoencephalopathy in a patient with Progressive multiple sclerosis treated with Ocrelizumab monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMa Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106416_bib0026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrneurol.2017.161","article-title":"Multiple sclerosis: progressive multifocal leukoencephalopathy risk stratification","volume":"13","author":"Pitarokoili","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106416_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106416_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105632","article-title":"Latent tuberculosis prevalence, diagnosis and treatment in Multiple Sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapy","volume":"86","author":"Reis","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106416_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu Rev. Pathol."},{"issue":"9","key":"10.1016\/j.msard.2025.106416_bib0028","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1007\/s00415-019-09397-8","article-title":"Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study","volume":"266","author":"S\u00f6derholm","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106416_bib0014","series-title":"Calend\u00e1rios De Vacina\u00e7\u00e3o SBIm Pacientes especiais: 2023-2024","year":"2023"},{"issue":"6","key":"10.1016\/j.msard.2025.106416_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2099171","article-title":"Vaccinations in patients with multiple sclerosis: a real-world, single-center experience","volume":"18","author":"Sbragia","year":"2022","journal-title":"Hum. Vaccin. ImmunOther"},{"issue":"6","key":"10.1016\/j.msard.2025.106416_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2099171","article-title":"Vaccinations in patients with multiple sclerosis: a real-world, single-center experience","volume":"18","author":"Sbragia","year":"2022","journal-title":"Hum. Vaccin. ImmunOther"},{"key":"10.1016\/j.msard.2025.106416_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104871","article-title":"Toxoplasma gondii and multiple sclerosis: a population-based case-control seroprevalence study, Central Anatolia, Turkey","volume":"78","author":"Sevimligul","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106416_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/0004-282x-anp-2022-s121","article-title":"Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review","volume":"80","author":"Silva","year":"2022","journal-title":"Arq. Neuro-Psiquiatr"},{"key":"10.1016\/j.msard.2025.106416_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104840","article-title":"Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs","volume":"77","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106416_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.msard.2025.106416_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s42466-019-0030-4","article-title":"Human immunodeficiency virus and multiple sclerosis: a review of the literature","volume":"20","author":"Stefanou","year":"2019","journal-title":"Neurol. Res. Pract."},{"issue":"12","key":"10.1016\/j.msard.2025.106416_bib0036","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1080\/21645515.2019.1657353","article-title":"Utility of serological screening for measles, mumps and rubella in immunocompromised patients","volume":"15","author":"Sticchi","year":"2019","journal-title":"Hum. Vaccin. ImmunOther"},{"issue":"2","key":"10.1016\/j.msard.2025.106416_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106416_bib0005","first-page":"988","article-title":"Epidemiology and pathophysiology of multiple sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"Continuum (Minneap. Minn)"},{"issue":"10","key":"10.1016\/j.msard.2025.106416_bib0039","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106416_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103236","article-title":"Vaccine hesitancy among people with multiple sclerosis","volume":"56","author":"Yap","year":"2021","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T17:34:44Z","timestamp":1747244084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S2211034825001580"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106416","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106416"}}